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Summary.-A comparative study of the effects of BCG, Micrococcus lysodeikticus, and
a series of structurally related polysaccharides (complement triggers) on the non-
specific and specific immune resistance against L1210 lymphoid leukaemia was
carried out and commented on. In contrast with authors of earlier reports, we were
unable to generate any effective non-specific or specific immunotherapy after the
graft of 104 leukaemic cells to 8-10-week-old CDF1 mice. However, when mice were
prevaccinated with irradiated (8 krad X-rays) cultured cells combined with 1 mg of
bacterium or polysaccharide one month before grafting 10 cells, they were given an
immunoprotection that was more pronounced with the i.p. than with the i.v. route.
Prevaccinated mice were afforded a stronger immunoprotection when boosted
repeatedly with 1mg injections of bacterium or polysaccharide after tumour
challenge.
IT is now clearly established that the
administration, before the graft of a
tumour, of adjuvants (Old et al., 1959) or
of irradiated tumour cells (Glynn et al.,
1963) can inhibit the growth of trans-
plantable tumours in rodents. Mathe
et al. (1969) have introduced the concept
of active anti-tumour immunotherapy.
They demonstrated conclusively that ac-
tive immunotherapy by BCG and Coryne-
bacterium parvum combined with irra-
diated leukaemic cells may strongly con-
trol the proliferation of L1210 leukaemia.
Numerous further reports have described
the protecting effect of BCG and anaero-
bic C. parvum against many syngeneic
mouse tumours (see Milas & Scott, 1978;
Mitchell, 1976). Although adjuvants such
as BCG may exert various biological
activities, like, for instance, T cell adju-
vant (Miller et al., 1]973), induction of
natural killer cells (Seth et al., 1976),
increased lymphocyte trapping (Zatz,
1976) and induction of T-cell-independent
B responses (Sultzer, 1978), the general
use of BCG has many disadvantages:
BCG can cause ulceration, pyrexia, liver-
function abnormalities, tuberculosis and,
in a few reported cases, death or even
enhancement of tumour growth (Mansell
& Krementz, 1973; Spark et al., 1973;
Hunt et al., 1973).
Therefore, it was important to define
the "active substance" of the bacterium,
or to search for new compounds with
similar biological properties. There is
increasing evidence that an effective
antineoplastic immune reactivity is in-
duced by activated macrophages and
phagocytes (Evans & Alexander, 1972)
that express membrane receptors for the
complement component C3 (Hainz, 1968).
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Complement activation is a very im-
portant step in inflammation that switches
on multiple biological processes such as
B-cell proliferation, macrophage activa-
tion (Bianco et al.,1976) and attraction of
polynucleated cells to the inflammation
site (WVard, 1967). These phenomena
occur after binding of the activated
compounds on specific membrane re-
ceptors (C3b or C3d) and are non-lytic to
the affected cell.
Especially for the macrophage, the
complement-induced signal leads to acti-
vation followed by extrusion of the
lysosomal content into the surrounding
mediuin (Schorlemmer et al., 1976). We
have previously demonstrated that the
Gram-positive but non-pathogenic bac-
terium Micrococcus lysodeikticus (ATCC
4698) is able to activate complement by
the alternative pathway (Verloes et al.,
1977). In this study, we investigate the
therapeutic values of this bacterium with
the activity generated by structurally
related complement-triggering polysac-
charides and BCG. Many of these
polysaccharides are active on a wide
variety of rodent tumours, but this study
aims at comparing their activity on a
transplantable leukaemia, an often-sol-
icited model forpreclinical chemotherapeu-
tic drug screening (Geran et al., 1972).
Special attention was paid to the choice of
treatment schedules in order to determine
experimental parameters that yield an
o)timal anti-tumour immune resistance.
MATERIAL AND METHODS
Micrococcus lysodeikticus.-A suspension
was made oflyophilized M. lysodeikticus (ML)
(Worthington Biochem. Corporation) after
repeated washings and centrifugations at
3000 g for 15 min at 4°C in phosphate-
buffered saline (PBS: 0-15 M Nacl, 0-01 M
potassium phosphate; pH 7.3). Bacteria were
heat-killed by incubation at 60°C for 30 min
and used within 1 week.
Bacillus Calmette-Gue'rin.-100 mg vials of
lyophilized Bacillus Calmette-Gue'rin for scari-
fication (BCG-SP) were purchased from the
Pasteur Institute, Brussels.
After recombination with the appropriate
diluent and further dilution in Hank's
balanced salt solution, the suspension was
kept at 4°C and used within 2 weeks.
Cell wall of ML, cell-wall-conjugated chitin
and chitin.-These were prepared as described
earlier (Verloes et al., 1976).
Zymosan A.-The cell wall of Saccharo-
myces cerevisiae yeast was commercially
available (Lot No. 34C-2650-Sigma Com-
pany). The insoluble cell walls were boiled
for 1 h in0-9% NaCl solution, washed 3 times
with PBS and centrifuged at 3000 g for 20
min.
Inulin.-The polyfructoside inulin (Lot
No. 519 903) was obtained from J. T. Baker
Company.
Dextran sulphate (sodium salt).-The ma-
terial used was a polysaccharide with a mol.
wt of approximately 500,000, and was pur-
chased from Pharmacia Fine Chemicals (Lot
No. 7126).
Quantitative agglutination analyses.-These
were carried out in U-shaped wells of Linbro
agglutination plates. 0 05 ml ofthe antiserum
was mixed with 0-05 ml of PBS and con-
secutive two-fold dilutions were made. After
a preincubation of' 30 min at 37°C, 0-05 ml
of the ML suspension (2 mg/ml) were added
and the agglutination was scored after 2 h at
37°C and expressed in log2 units.
Animals.-Female CDF1 (H2d) hybrid
[female BALB/c (H2d) x male DBA/2
(H2d)] F1 animals were purchased from
Charles River Breeding Laboratories, Calco,
Italy. Those mice were stored for at least 3
weeks in an isolation room and were used
before they were 10 weeks old. Animals
weighing 19-23 g were used.
Tumour.-L1210 lymphoid leukaemia was
originally obtained from Mr I. Wodinsky
(Arthur D. Little, Inc., Cambridge, Mass.,
U.S.A.). This tumour was maintained in
DBA/2 mice by weekly i.p. inoculation.
L1210 cells were aspirated from DBA/2 mice
and a suspension was made in Hank's
balanced salt solution: 104 cells in 0.1 ml
solution were injected i.p. to obtain the
ascitic form ofleukaemia or i.v. to obtain the
blood form of the leukaemia. Animals were
randomized into test and control groups.
Ten to 20 mice were used for each experi-
ment.
Mean survival time (MST) ± the standard
deviation of treated and control mice as well
as the doses and timing of each experiment
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are specified in the tables. Mice that were
tumour-free on the 90th day after tumour
grafting were considered as long-term sur-
vivors and were eliminated from calculation
of the mean survival time and the standard
deviation. The ratio of MST of treated mice
to controls is expressed. Although it was
often difficult to support considerable in-
creases in MST of treated mice over the
controls by Student's t test (because of high
standard deviations), we considered the
percentage of long-term survivors to be the
best evaluation.
Specific immunotherapy.-Tumour cells
were harvested from the peritoneal cavity of
a DBA/2 mouse bearing a 7-day-old L1210
tumour (105 cells grafted on Day 0) and
grown without antibiotics as suspension
cultures in Roswell Park Memorial Institute
Medium 1640 (RPMI) supplemented with
10% heat-inactivated foetal calf serum.
Tumour cells were routinely passaged as
stationary cultures in Falcon 3024 flasks or
grown to plateau phase (2-5 x 106 cells/ml)
inspinner cultures 24 h beforetheexperiment.
Cultured cells were spun down and adjusted
to 5 x 107/ml RPMI. After irradiation of
8000rad (250 kV, 12 mA, 95 rad/min, X-
rays, 0-5 mmCu + 0-5 mm Al filtration) 107
cells were grafted to CDF1 mice.
RESULTS
1. Effect ofpre-treatment on mouse survival
First we investigated the immuno-
prophylactic capability of Micrococcus,
injected i.p. at different doses, 14 days
before grafting 104 leukaemic cells into
the mouse peritoneum. None of the doses
(0-01, 0-05. 0-25, 0-75 or 1-5 mg) was able
to prolong MST of pretreated mice com-
pared to control mice. Neither were
single injections of I mg of ML, BCG,
dextran sulphate, cell wall of ML, zymo-
san A or chitin, suspended in PBS or in
incomplete Freund's adjuvant, effective
against 104 cells inoculated i.p. 14 days
later. Also, when mice were given i.p.
injections of ML, BCG, dextran sulphate,
cell wall of ML, zymosan A, cell-wall-
conjugated chitin or chitin on Days
1, 4, 7, 10 and 13 and were tumour-
challenged (104 cells, i.p.) on Day 31,
they were not immunoprotected.
However, when mouse sera taken from
the retro-orbital plexus on Day 25 were
analysed, we found positive agglutina-
tion patterns with 2 mg/ml micrococcus
suspension for micrococcus (log2 = 6-42 ±
1.86), zymosan A (log2 = 1-9 ± 2.25),
inulin (log2 2-05 ± 1.42), chitin (log2
1-5 + 0 87) and cell-wall-conjugated chit-
in (log _ 0-29 + 0-39).
However positive agglutination pat-
terns due to cross-reactions of immuno-
globulins with micrococcus epitopes were
never detected in sera of BCG or dextran-
sulphate-treated mice.
2. Effect of (specific) immunotherapy with
Micrococcus, BCG, and related polysaccha-
rides on murine L1210 leukaemia growth
Randomized mice were challenged with
104 L1210 cells i.p. on Day 0. Mice were
treated with ML injections either on
Days 1, 2, 3, 4 and 5 or on Days 1, 4, 7 and
10. Neither dose (0-01-1-5 mg) adminis-
tered i.p. could affect leukaemia growth.
Similarly, we were unable to prolong
mean survival time of leukaemic mice
by i.p. treatment with 1 mg of ML,
BCG, dextran sulphate, cell wall of ML,
zymosan A, or chitin given either on
Days 1, 2, 3, 4 and 5 or on Days 1, 4, 7
and 10.
Then we investigated whether Micrococ-
cus, BCG, or complement-triggering poly-
saccharides could induce a specific anti-
tumour immune reaction when adminis-
tered together with irradiated (8 krad
X-rays) cultured L1210 cells. Mice were
given i.p. or i.v. a transplant of 104
L1210 leukaemic cells on Day 0. Animals
were treated i.p. with a single injection
of 107 irradiated cultured L1210 cells
combined with 1 mg of different agents
24 h after tumour grafting. Treatment by
1 mg injections was continued on Days
4, 7 and 10 or on Days 2, 3, 4 and 5.
Neither injection of irradiated cultured
L1210 cells alone, nor injection of irradia-
ted cells combined with bacteria or
polysaccharide, provided any anti-tumour
immune resistance, irrespective of the
route of inoculation.R. VERLOES, G. ATASSI, P. DUMONT AND L. KANAREK
TABLE I.-Specific anti-L1210 immunoprophylaxis exerted by prevaccination with
irradiated cells and Micrococcus, BCG or related polysaceharides
Treatmentt
Agent
BCG
Micrococcus
Zymosan A
Chitin
Dextran sulpha
(control)
(control)
BCG
Micrococcus
Zymosan A
Chitin
Dextran sulphal
(control)
(control)
Treatment
and
transplant
route
i.p.
i.p.
i.p.
i.p.
te i.p.
i.p.
i.p.
i.v.
i.v.
i.v.
i.v.
te i.v.
i.v.
i.v.
MST§
± s.d.
(days)
26-0±4 08*
16-4±3-89*
25-4±2-07*
19-4±4-34*
17 -2±7 -98
15-0±2-73*
9-8±0-79
19-0±8-12*
15-5±5-24*
32 -6±40 - 73
15-4±3-43*
14-0±3 -37
LBAt
9 00 -77
T/C %
265
167
259
198
176
153
100
211
172
362
171
156
100
0/, of long-term
survivors
(Day 90)
50
0
29
0
0
0
0
0
0
17
0
0
0
* Significant at P < *001 level.
t Lost by accident.
$ Intact CDF1 mice were vaccinated by grafting 107 irradiated (8 krad, X-rays) cultured L1210 cells and
1 mg of different agents one month before transplantation of 104 leukaemic cells.
§ Mean survival time.
3. Specific anti-LI210 immunoprophylaxis
by prevaccination with irradiated cells
and administration of Micrococcus, BCG,
or related polysaccharides
CDF1 mice were vaccinated by grafting
107 irradiated (8 krad X-rays) cultured
L1210 cells and by injecting 1 mg of
different agents i.p. or i.v. 1 month before
inoculation of 104 leukaemic cells. Mice
received a tumour challenge of 104 L1210
cells using the vaccination route. I.p.
prevaccination with BCG, ML, zymosan A,
chitin, dextran sulphate or irradiated
cells alone increased MST by 165, 67, 159,
98, 76 and 530/o respectively as compared
to control mice, whereas the i.v. treat-
ment resulted in an increase in mean
survival time of 111, 72, 262, 71 and 56%
respectively. I.p. prevaccination with
BCG yielded 50% of long-term survivors,
but i.v. treatment yielded none, whereas
the i.p. or i.v. prevaccination with zymo-
san A induced 29 and 17% of long-term
survivors, as illustrated in Table I.
4. Effect of prevaccination on the specific
immunotherapy with Micrococcus, BCG,
or related polysaccharides
Since in the preceding experiment the
i.p. route was shown to be the best
therapeutic route, CDF1 mice were vac-
cinated i.p. with 107 irradiated (8 krad
X-rays) cultured leukaemic cells and 1 mg
injections of different agents, 1 month
before tumour grafting.
Mice were challenged i.p. with 104
L1210 leukaemic cells on Day 0. Some
animals were inoculated with irradiated
cultured cells (107) and 1 mg of bacteria
or polysaccharide, some with 1 mg of
bacteria or polysaccharide alone, 24 h
after tumour challenge. Treatment was
continued by giving 1 mg i.p. injections
on Days 4, 7, 10 and 13. The results ofthe
different treatments are presented in
Table II. When compared with the data
obtained by prevaccination alone, these
results show conclusively that repeated
1 mg injection of bacteria or polysaccha-
ride (after tumour grafting) may favour-
ably increase the MST of treated mice
and induce a high percentage of long-
term survivors. A rechallenge with 107
irradiated cultured cells 24 h after tumour
grafting may sometimes lower the im-
munoprotection presumably due to com-
petition of irradiated cells with viable
cells.
Irradiated
cells
+
+
+
+
A-
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TABLE II.-Effect of prevaccination with micrococcus, BCG or related polysaceharides
on murine L1210 leukaemia growth
Treatment*
107 irradiated cells
Day-30/Day +1
± +
+ +
± +
+ +
+ +
± +
+ +
+ +
±
+-
+-
+-
+-
+-
+
Agent
BCG
Micrococcus
Cell-wall ML-chitin
Chitin
Dextran sulphate
Zymosan A
Inulin
- (control)
BCG
Micrococcus
Cell-wall ML-chitin
Chitin
Dextran sulphate
Zymosan A
Inulin
- (control)
- (control)
MST ± s.d.t (days)
33-3±10 021
14-3±2 -31
16 5±4 04
24-0±14-28
14-0±2 -64
19 0±4-95
13 -2±0-50
20-0±19-0
23*0±2 lt
17 .0±5 .20
21-5±1-73t
17-0±4-24
15-5±4- 72
26-0±17- 35
20-8±6-79t
13 00 ±0
13-3±0 49
T/C %
251
107
124
181
105
143
100
150
173
128
162
128
117
196
157
98
100
% of long-term
survivors (Day 90)
57
33
50
14
0
17
33
0
86
50
33
75
0
50
0
0
0
* Intact CDF1 mice were vaccinated i.p. 1 month before tumour grafting with 107 irradiated (8 krad
X-rays) cultured leukaemic cells and 1 mg injections of different agents. On Day 0, mice were challenged
i.p. with 104 L1210 leukaemic cells and some were treated i.p. by 107 irradiated cultured cells on Day 1.
Treatment was continued by giving lmg i.p. injections on Days 1, 4, 7, 10 and 13.
t Mean survival time.
: Significant at P < *001 level.
DISCUSSION
Previous studies have demonstrated
that immuno-stimulating compounds such
as levamisole (Johnson et al., 1975) or
BCG (Mathe et al., 1969) were successfully
used to reinforce the immunological po-
tential of mice bearing transplantable
tumours. Macrophages and phagocytes are
mediators of immune processes, and also
have a strong anti-neoplastic cytotoxic
potential (Evans & Alexander, 1972).
Since those particular cell types are known
to be activated through the serum com-
plement system (Bianco, et al.,1976), we
have compared the therapeutic activity
of the complement activator Micrococcus
lysodeikticus with that of the related
complement - triggering polysaccharides
and BCG. In a first experiment, pre-
treatment with different doses of ML or
with 1 mg injections of ML, BCG, or
polysaccharide suspended in PBS or in
incomplete Freund's adjuvant, was un-
able to affect L1210 leukaemia growth.
Multiple injections of ML or polysac-
charide induce the production of cross-
reacting immunoglobulins. It would be
41
interesting to investigate whether this
humoral immunity prevents or enhances
the C3-cleaving activity and the mobiliza-
tion of phagocytes. In contrast to data
reported by Mathe et al. (1969), we
repeatedly failed to prolong MST of
leukaemic mice by i.p. injections of 1 mg
of BCG, ML or polysaccharide on Days
1, 2, 3, 4 and 5 or on Days 1, 4, 7 and 1(1.
In further experiments, repeated i.p.
administration of ML, BCG or polysac-
charide, together with 107 of irradiated
(8 krad) cultured leukaemic cells was
unable to affect i.v.- or i.p.-transplanted
104 leukaemic cells. This discrepancy
cannot be due to the dose and timing
nor to the irradiation (which was used at
the optimal dosage). While active im-
munotherapy of L1210 leukaemia (H2d
cells), as described by Mathe (1969),
was performed on [C57 BL (H2k) x
DBA/2 (H2d)] F1 hybrid (BDF1) mice,
we used [Balb/c (H2d) x DBA/2 (H2d)]
F1 hybrid CDF1 mice and it is possible
that the strength of anti-tumour im-
munoresponse may differ according to
mouse genotype. However, with young604 R. VERLOES, G. ATASSI, P. DUMONT AND L. KANAREK
mice it is hard to assume that differences
in histocompatibility may account for
earlier acquisition of immunity.
Furthermore, if activation of macro-
phages by BCG requires a T-cell adjuvant
effect, as C. parvum does (Sljivic &
Watson, 1977), it is worth mentioning
that BCG adjuvant activity becomes
significant only after 2 weeks (Mathe et al.,
1973). This is probably too long a lag for
immunotherapy to be effective against
neoplasms that kill untreated mice 10
days after tumour grafting.
However, when CDF1 mice were pre-
vaccinated by grafting 107 irradiated
cultured L1210 cells and by injecting
i.v. or i.p. 1 mg of different agents 1
month before tumour grafting, they were
provided with an effective anti-tumour
immune resistance against 104 leukaemic
cells grafted by the vaccination route.
When prevaccinated mice (107 irradiated
cultured cells + 1 mg bacterium or poly-
saccharide) received 1 month later a
transplant of 104 leukaemic cells, they
showed a better immune resistance when
boosted on Days 4, 7, 10 and 13 with 1 mg
of bacterium or polysaccharide than when
rechallenged with 107 irradiated L1210
cells and complement trigger (Day 1) and
boosted on Days 4, 7, 10 and 13 with
complement activators only.
According to the immunostimulation
theory of Prehn (1972) a minimal immune
response to tumour cells accelerates tum-
our growth, whereas a vigoronsreaction is
cytotoxic. Consequently, the challenge of
mi.ce w1ith high doses of tumour cells may
weaken the effectiveness of immune-bell
proliferation from the day of tumour
grafting. High doses of rapidly proliferat-
ing leukaemia cells may soon exceed the
immune capacity ofmice and dramatically
counterbalance the immune-effector-cell:
tumour-cell ratio. However, secondary
immune responses of mice sensitized
before tumour grafting may yield stronger
and earlier immune responsiveness leading
to effective immunotherapy, as illustrated
in Table II.
The i.p. route was found to be more
effective than the i.v.; it increased MST
over controls and induced survivors to
Day 90 after tumour grafting. This is not
surprising, since intratumoral treatments
have yielded optimal results in other
tumour systems also (Pinsky et al., 1973;
Zbar et al., 1971).
Since L1210 leukaemia kills untreated
mice early and with small standard
deviations, it offers the most highly
recommended and reliable animal tumour
model that allows activity prediction
against human leukaemia (Geran et al.,
1972) after drug screening, immuno-
prophylactic or chemo-immunotherapeu-
tic studies. However, its usefulness for
pure immunotherapeutic investigations is
questionable. Clearly, clinical immuno-
therapy requires more fundamental know-
ledge of immunological mechanisms and
optimal treatment parameters obtained
from adequate preclinical animal models,
to be successful against human neoplasms.
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